Spasticity drugs market seen reaching $5.58B by 2030

The Business Research Company says the global spasticity management drugs market is set to rise from $3.99 billion in 2025 to $4.26 billion in 2026, then reach $5.58 billion by 2030. The report points to growing neurological disease burden, aging populations and broader access to care as key demand drivers.

Why it matters: - Spasticity management drugs are used to reduce muscle stiffness, spasms and pain tied to neurological conditions. - Rising demand for these therapies signals more need for treatment in stroke, cerebral palsy, multiple sclerosis and other nervous system disorders. - The market outlook also reflects broader pressure on healthcare systems to expand rehabilitation and neurology care.

What happened: - The Business Research Company released its "Spasticity Management Drugs Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035" on July 22, 2026. - The report projects the market will grow from $3.99 billion in 2025 to $4.26 billion in 2026. - The report forecasts the market will reach $5.58 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region over the forecast period.

The details: - The 2026 forecast implies a 6.8% compound annual growth rate. - The 2030 forecast implies a 7.0% compound annual growth rate. - The report links near-term growth to more neurological disorders, including stroke and cerebral palsy. - Traditional muscle relaxants remain limited, which supports demand for other treatment options. - A rising elderly population is increasing mobility-related care needs. - Broader awareness of rehabilitative medicine is supporting adoption. - Hospitals are using more neurology-focused treatments for spasticity management. - Longer-term growth is expected from targeted neuro-modulating drugs. - Wider acceptance of botulinum toxin therapies is another growth driver. - Demand is rising for less invasive treatments. - Precision medicine is gaining ground in neurology. - Rehabilitation-centered healthcare infrastructure is expanding. - The report says spasticity drugs help improve mobility, reduce pain and support daily activities. - The report also includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available through the company’s sample request page. - The full report is available on The Business Research Company’s report page.

Between the lines: - The report frames the market as a steady-growth category rather than a breakout one. - Aging populations and neurological disease prevalence are doing most of the heavy lifting on demand. - Infrastructure expansion matters because access to specialists and rehabilitation services can determine whether patients stay on treatment. - The emphasis on botulinum toxin, precision medicine and less invasive care suggests the market is moving toward more targeted therapy.

What's next: - The market is expected to keep expanding through 2030 as diagnosis, care access and treatment options widen. - Regional growth in Asia-Pacific will likely depend on continued healthcare investment and awareness of neurological disorders. - Product strategies will probably focus on targeted therapies and rehabilitation-linked care pathways. - The Business Research Company says its 2026 reports also include Global Market Model forecasting support and other strategic tools for decision-making.